121 related articles for article (PubMed ID: 25425069)
1. The position of blonanserin as a treatment for schizophrenia.
Kishi T; Matsuda Y; Iwata N
Asia Pac Psychiatry; 2014 Dec; 6(4):462. PubMed ID: 25425069
[No Abstract] [Full Text] [Related]
2. Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial.
Yang J; Bahk WM; Cho HS; Jeon YW; Jon DI; Jung HY; Kim CH; Kim HC; Kim YK; Kim YH; Kwon JS; Lee SY; Lee SH; Yi JS; Yoon BH; Kim SH
Clin Neuropharmacol; 2010 Jul; 33(4):169-75. PubMed ID: 20661022
[TBL] [Abstract][Full Text] [Related]
3. [Blonanserin in the treatment of schizophrenia].
Tenjin T; Miyamoto S
Nihon Rinsho; 2013 Apr; 71(4):660-5. PubMed ID: 23678596
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Kishi T; Matsui Y; Matsuda Y; Katsuki A; Hori H; Yanagimoto H; Sanada K; Morita K; Yoshimura R; Shoji Y; Hagi K; Iwata N
Pharmacopsychiatry; 2019 Feb; 52(2):52-62. PubMed ID: 29514360
[TBL] [Abstract][Full Text] [Related]
5. Blonanserin: a review of its use in the management of schizophrenia.
Deeks ED; Keating GM
CNS Drugs; 2010 Jan; 24(1):65-84. PubMed ID: 20030420
[TBL] [Abstract][Full Text] [Related]
6. Three cases of schizophrenia showing improvement after switching to blonanserin.
Kurotaki N; Nobata H; Nonaka S; Nishihara K; Ozawa H
Psychiatry Clin Neurosci; 2011 Jun; 65(4):396-7. PubMed ID: 21682816
[No Abstract] [Full Text] [Related]
7. Blonanserin, a novel antipsychotic, is suitable for treating schizophrenia associated with hyperprolactinemia: a case series.
Kawabe K; Horiuchi F; Ueno S
Clin Neuropharmacol; 2013; 36(6):239-41. PubMed ID: 24201238
[TBL] [Abstract][Full Text] [Related]
8. Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
Kishi T; Matsuda Y; Iwata N
PLoS One; 2014; 9(2):e88049. PubMed ID: 24505373
[TBL] [Abstract][Full Text] [Related]
9. Blonanserin patch vs. Other Antipsychotics for Acute Schizophrenia: A Systematic Review of Double-blind, Randomized, Placebo-controlled, Phase 3 Trials in Japan.
Kishi T; Yoshimura R; Matsuda Y; Sakuma K; Iwata N
Pharmacopsychiatry; 2020 Apr; 53(3):122-132. PubMed ID: 32000271
[TBL] [Abstract][Full Text] [Related]
10. One-year follow-up study of psychotic patients treated with blonanserin: a case series.
Takahashi S; Suzuki M; Uchiyama M
Asia Pac Psychiatry; 2013 Sep; 5(3):164-7. PubMed ID: 23857800
[TBL] [Abstract][Full Text] [Related]
11. Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
Miura I; Shiga T; Katsumi A; Kanno-Nozaki K; Mashiko H; Niwa S; Yabe H
Hum Psychopharmacol; 2014 Mar; 29(2):199-202. PubMed ID: 24590545
[TBL] [Abstract][Full Text] [Related]
12. Model-based analysis of therapeutic efficacy of blonanserin and risperidone in schizophrenia patients and effects on prolactin: A randomized double-blind study.
Yu W; Lei L; Yu Y; Li Y; Shen Y; Li H
Hum Psychopharmacol; 2020 Jan; 35(1):e2717. PubMed ID: 31837240
[TBL] [Abstract][Full Text] [Related]
13. Blonanserin ameliorated the tendency toward QTc prolongation associated with risperidone in a patient with schizophrenia.
Mizuki Y; Takaki M
J Clin Psychopharmacol; 2015 Feb; 35(1):101-2. PubMed ID: 25502488
[No Abstract] [Full Text] [Related]
14. [Treatment of schizophrenia with imiclopazine, pimozide, imagotan and trifluorperidol. Comparative study].
Nurowska K; Welbel L
Psychiatr Pol; 1973; 7(1):57-63. PubMed ID: 4146043
[No Abstract] [Full Text] [Related]
15. [Pharmacological profiles and clinical effects of blonanserin (Lonasen) on schizophrenia].
Ishibashi T; Nishikawa H; Une T; Nakamura H
Nihon Yakurigaku Zasshi; 2008 Dec; 132(6):351-60. PubMed ID: 19075531
[No Abstract] [Full Text] [Related]
16. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
17. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
18. Adjunctive treatment with low-dosage aripiprazole for blonanserin-induced hyperprolactinemia in a female patient with schizophrenia.
Ishitobi M; Kosaka H; Shukunami K; Murata T; Wada Y
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1361-2. PubMed ID: 20647025
[No Abstract] [Full Text] [Related]
19. Quetiapine-induced insulin resistance after switching from blonanserin despite a loss in both bodyweight and waist circumference.
Suzuki Y; Sugai T; Fukui N; Watanabe J; Ono S; Tsuneyama N; Saito M; Someya T
Psychiatry Clin Neurosci; 2012 Oct; 66(6):534-5. PubMed ID: 23066773
[No Abstract] [Full Text] [Related]
20. Olfactory reference syndrome treated by blonanserin augmentation.
Takekita Y; Kato M; Sakai S; Suwa A; Nishida K; Tajika A; Yoshimura M; Kinoshita T
Psychiatry Clin Neurosci; 2011 Mar; 65(2):203-4. PubMed ID: 21414096
[No Abstract] [Full Text] [Related]
[Next] [New Search]